MiniMed Flex™ Now Available for Medicare Beneficiaries: Advancing Diabetes Management

MiniMed has announced that Medicare and Medicare Advantage beneficiaries in the U.S. now have access to the MiniMed Flex™ insulin pump system, featuring the latest sensor technology. This expansion boosts the availability of MiniMed's compact, app-controlled insulin pump for diabetes management. The device, about half the size of previous models, maintains a 300-unit insulin capacity and includes SmartGuard™ technology, automatically adjusting insulin delivery every five minutes.

Clinical data from the American Diabetes Association's scientific sessions reveal that users of the MiniMed™ 780G system, employing similar technology, have surpassed recommended glycemic control benchmarks. This illustrates the potential advantages for Medicare users now eligible to adopt this technology. MiniMed CEO, Que Dallara, highlighted the importance of broadening access to the MiniMed Flex™, as it simplifies diabetes management, alleviating the constant attention typically required.

Currently, the MiniMed Flex™ system is integrated with the Simplera Sync™ sensor and will soon support Abbott’s Instinct sensor. The system's discreet functionality via an app is highly praised, as it allows users greater focus on personal pursuits. For further details or purchasing information, stakeholders are encouraged to visit MiniMed’s official website. As a prominent player in the diabetes management industry, MiniMed continues to advance insulin delivery systems and support services, reinforcing its commitment to enhancing the daily lives of those affected by diabetes.

The company's forward-looking statements are subject to risk factors, as disclosed in their filings with the Securities and Exchange Commission, which could impact future outcomes.